In high-risk stage II CRC, shorter oxaliplatin-based adjuvant chemotherapy gives mixed results

  • Petrelli F & al.
  • JAMA Oncol
  • 13 févr. 2020

  • Par Jim Kling
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • In clinical high-risk, stage II colorectal cancer (CRC), 6 months of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) led to better 5-year relapse-free survival (RFS) than 3 months, but 3 months of CAPOX (capecitabine plus oxaliplatin) was noninferior to 6 months.

Why this matters

  • 3 months of CAPOX and 6 months of FOLFOX are viable options.

Study design

  • Preplanned subgroup analysis of patients with stage II CRC in a phase 3, randomized, controlled trial (TOSCA, n=1254) that compared treatment with FOLFOX or CAPOX for 3 or 6 months.
  • Funding: Italian Group for the Study of Digestive Tract Cancers Foundation; Agenzia Italiana del Farmaco.

Key results

  • Median follow-up, 62 months; 24.0% pT4N0M0 tumors, 76.0% high-risk pT3N0M0 tumors.
  • 61.9% received FOLFOX, 38.1% CAPOX.
  • Among those who underwent 3 months of treatment, 5-year RFS was 82.2% vs 88.2% for 6 months (HR, 1.41; P=.02 for superiority).
  • In the CAPOX regimen, 3 months was noninferior to 6 months with respect to 5-year RFS (HR, 1.13; 95% CI, 0.70-1.84).
  • In the FOLFOX regimen, 6 months was associated with better RFS (HR, 1.58; 95% CI, 1.09-2.28).
  • The 6-month group had a greater frequency of grade 3-4 neuropathy (8.4% vs 1.3%; P<.001>

Limitations

  • Secondary analysis.